Kornimate/medical-research-clean huggingface dataset:
assessment of renal function in cirrhotic patients

Conditions: Liver Failure; Renal Failure

Summary: the purpose of this study is to help determine whether cystatin c is a more sensitive laboratory measurement for renal function in cirrhotic patients.

serum cystatin c, creatinine clearance based calculations, and 125i-iothalamate clearance (glofil) will be obtained in 220 patients with cirrhosis. utilizing this information, the correlation between cystatin c and 125i-iothalamate clearance will be obtained. in addition, the current serum creatinine based calculations and true creatinine clearance will also be correlated with 125i-iothalamate clearance. the results of this study should help to determine whether serum cystatin c is a more sensitive laboratory measurement of renal function in patients with cirrhosis.

Eligibility criteria:
inclusion criteria: * over 18 undergoing evaluation for a liver transplant exclusion criteria: * known allergy or sensitivity to 125i-iothalamate

Keywords: renal function cirrhotic patients transplant evaluation
probiotics effect on glucose and lipid metabolism and gut microbiota in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine whether the probiotics is effective in the treatment of type 2 diabetes.

this study aims to evaluate the effect of probiotics on the improvement of glucose and lipid metabolism, as well as the gut microbiota.baseline, 1 month and 3 month data will be collected and put into analysis to provide some suggestions on the probiotics use in the clinical practice for type 2 diabetes patients.

Eligibility criteria:
inclusion criteria: 1. age 20-80 years 2. confirmed type 2 diabetes patients with oral antidiabetic agents 3. agree to cooperate in the trial 4. provision of written informed consent exclusion criteria: 1. with chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance 2. type 1 diabetes 3. treated with insulin or an insulin analogue in the last 6 months 4. use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, h2 blockers, proton pump inhibitors, corticosteroids or sex hormones 5. use any probiotics in the last 3 months 6. participating in any other clinical trials 7. was not able to insist until the end 8. pregnant and lactating women

Keywords: diabetes mellitus, type 2, probiotics, treatment
evaluation of the yofimeter glucometer

Conditions: Diabetes

Summary: this evaluation will evaluate a new system from yofimeter, known as yofilife blood glucose monitoring system with yofimeter glucometer. yofilife includes a web- based data system known as the web portal and smart phone apps for the iphone and android. the new yofimeter is similar to other glucometers with the exception of built in test cassettes, lancet cassettes with enhanced communications and data reviewing options. this evaluation will also collect data from a ysi 2300 stat plus glucose analyzer reference glucometer. the ysi 2300 stat plus glucose analyzer will be used as the "gold" standard with all results compared to the ysi results.

this is a single evaluation to assess both the yofimeter system accuracy in the hands of the intended users, as well as other aspects to support lay use, such as labeling assessment and usability. the company is presenting diabetics who monitor their blood glucose with new technological innovations aimed at improving their daily lives (e.g., a unique blood glucose monitor, web portal applications and "smart phone" applications). each subject selected for the comparison evaluation will perform their own fingerstick and test on their subject device following device instructions. a trained technician will perform a fingerstick on the subject immediately after and perform the test on the same device. separate results will be recorded by subject and technician. a trained technician will take another blood sample, within as short of a time as practicable, for a glucose assay on the ysi 2300 stat plus glucose analyzer.

Eligibility criteria:
inclusion criteria: 1. is the subject currently self-testing for blood glucose levels? 2. is the subject able to provide legal, written informed consent? 3. is the subject willing to have fingersticks for blood glucose determination? 4. does the subject show an ability and willingness to follow directions of the investigator and staff? 5. is the subject 18 years of age or older? 6. does the subject have a hematocrit value in the range of 20-60? exclusion criteria: 1. does the subject demonstrate a lack of compliance as determined by the principal or lead site investigator and/or staff? 2. is the subject currently participating in another clinical study of an investigational device or drug? 3. is the subject unwilling or unable to provide concurrent blood glucose level determinations with the yofimeter whenever blood glucose levels are determined at the investigator's site? 4. is the subject, or a family member, employed by a company that develops or markets blood glucose level determining devices? 5. does the subject have any other condition or finding, which in the opinion of the investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol? 6. is the subject unwilling or unable to provide informed consent (ic)?

Keywords: diabetes glucometer yofimeter diabetes monitoring
sti testing to enhance prep use in pregnancy

Conditions: PrEP Adherence; Sexually Transmitted Infections (STIs); Pregnancy

Summary: the investigators are conducting a study in botswana to see if offering sti testing along with expanded hiv prevention options (prep) helps more pregnant women start and continue using prep during and after pregnancy. pregnant women (n=600) seeking antenatal care in botswana will be enrolled and randomly assigned to receive the standard of care (standard sti assessment with no sti testing) versus sti testing for chlamydia trachomatis, neisseria gonorrhoeae and trichomonas vaginalis during pregnancy and postpartum. the investigators' hypothesis is that providing sti testing alongside prep offer will encourage more women to start and continue using prep.

the investigators are conducting a 2-arm 1:1 randomized trial to compare prep delivery with co-offer of sti testing for chlamydia trachomatis, neisseria gonorrhoeae and trichomonas vaginalis (using xpert ct/ng and tv assays) vs. standard-of-care (soc, syndromic management) among pregnant women without hiv (n=600) in botswana. antenatal care clients will be offered prep (self-select oral pills or dpv-vr). participants will be followed up to 9 months postpartum. women will be able to switch prep methods and start, stop, or restart prep at any time. primary outcomes are the proportion of clients who initiate prep, persist with use at 9 months postpartum, and adhere (quantified by hair drug levels). secondary outcomes are prep choice (pills vs. dpv-vr), sti rates, and birth outcomes by randomization arm. exploratory outcomes are hiv incidence, quality of care, adherence cofactors, and antimicrobial resistance.

Eligibility criteria:
inclusion criteria: * pregnant and seeking antenatal care * self-identifying as a cis-gender woman * living without hiv * not currently using prep * planning to remain in the city/town of enrolment until 9 months post-delivery. * planning to receive antenatal and postnatal care in the city/town of enrolment. * willing and able to provide informed consent exclusion criteria: * male gender * not pregnant * living with hiv * currently using prep * not planning to remain in the city/town of enrolment until 9 months post-delivery * not planning to receive antenatal and postnatal care in the city/town to enrolment * not able or willing to provide informed consent for participation

Keywords: pregancy prep hiv stis chlamydia gonorrhoea gonorrhea trichomonas dapivirine truvada oral prep
dialysate sodium individualization in hemodialysis

Conditions: Hypertension; Hemodialysis Patients

Summary: salt and water excess is an essential mechanism of hypertension. this is particularly relevant to patients with end stage kidney disease (eskd) on dialysis. we have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentration leads to less thirst, interdialytic weight gain, and better bp control in hypertensive patients. in this study we will evaluate the mechanisms underlying this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker of volume status.

recent evidence from our group shows that individualization of the sodium concentration in the dialysate to match the patient's own serum sodium results in less thirst, less interdialytic weight gain, less hd-related symptoms, and better blood pressure control in hypertensive subjects. in this project we will evaluate the effect of dialysate sodium individualization on systemic hemodynamics, body volume compartments and biochemical markers of volume control in hypertensive hemodialysis patients. we will use a single-blind cross-over design with randomized blocks. after a 3-week baseline period where pre-hd serum sodium will be measured weekly to establish each patient's average serum sodium, subjects will be randomized to 3 weeks on standard dialysate sodium (140 mmol/l) or individualized dialysate sodium (same concentration as the average pre-hd serum sodium during the baseline period), then crossed over to the other for another 3 weeks after a 1-week washout period (dialysate na 140 mmol/l). the remainder of the dialysis prescription, prescribed dry weight and vasoactive drugs will remain unchanged throughout the study. clinical information, pre/intra/post-hd blood pressure and thirst scores will be measured weekly at the mid-week dialysis session. in addition, we will measure systemic hemodynamics (cardiac output and systemic vascular resistance), bioimpedance measurements of intracellular and extracellular volume, arterial stiffness (aortic augmentation index, aortic pulse wave velocity), interdialytic (44h) ambulatory bp monitoring, and plasma bnp, renin, aldosterone and norepinephrine at baseline and at the end of each block.

Eligibility criteria:
inclusion criteria: * eskd on hemodialysis * hypertension, defined as average pre-hd bp \>150/85 mmhg or use of antihypertensive drugs * average pre-hd serum sodium \<139 mmol/l exclusion criteria: * intradialytic hypotension * atrial fibrillation or other chronic tachyarrhythmia (due to effects on measuring equipment) * uncontrolled hypertension (average pre-hd bp \>200/105 mmhg) * uncontrolled diabetes mellitus (due to problems on interpretation of serum sodium values) * debilitating illness * inability to provide written informed consent

Keywords: hypertension hemodialysis sodium dialysate hemodynamics
a study to evaluate sgb-3403 in healthy volunteers and subjects with elevated low-density lipoprotein cholesterol (ldl-c)

Conditions: Hyperlipidemias

Summary: this study is a randomized, double-blind, placebo-controlled, single ascending dose (sad) and multiple ascending doses (mad) of sgb-3403 when single administered subcutaneously to healthy volunteers and multiple administered subcutaneously to subjects with elevated ldl-c to evaluate the safety, tolerance, pk, and pd.

this study is a randomized, double-blind, placebo-controlled, single ascending dose (sad) and multiple ascending doses (mad) of sgb-3403 when single administered subcutaneously to healthy volunteers and multiple administered subcutaneously to subjects with elevated ldl-c. the study will be performed in 2 phases: sad and mad.

Eligibility criteria:
inclusion criteria in sad: * male and female subjects aged 18 to 55 years are included. * body mass index between 19 and 32 kg/m2, inclusive. * physical examination, vital signs, 12-lead electrocardiogram, and laboratory tests will be normal or slightly abnormal but not clinically significant according to the investigator's judgment. * willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent. exclusion criteria in sad: * an underlying known disease or surgical or medical condition that, in the opinion of the investigator, might interfere with the interpretation of the clinical study results. * the positive result of hepatitis b surface antigen (hbsag), hepatitis c virus antibody (hcv ab), human immunodeficiency virus (hiv) antibody, or syphilis at screening. * alanine aminotransferase (alt), total bilirubin (tbil), aspartate aminotransferase (ast), alkaline phosphatase (alp), or gamma-glutamyl transferase (ggt) \> 1.5 × uln (upper limit of normal). * serum creatinine exceeds the upper limit of normal at screening. * history of multiple drug allergies or allergic reactions to an oligonucleotide or n acetylgalactosamine (galnac). * history of intolerance to subcutaneous (sc) injection or relevant abdominal scarring (surgical, burns, etc.) * received an investigational agent within 28 days or 5 half-lives (whichever is longer) before the first dose of the study drug or are in another clinical study, received inclisiran within 1 year. * use any chinese herbs, vitamins, or supplements known to affect lipid metabolism (e.g., fish oil \> 1000 mg/ day, medicines, or health products containing red yeast rice) within 28 days before receiving the test drug. * any conditions which, in the opinion of the investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study. inclusion criteria in mad: * male and female subjects aged 18 to 65 years are included. * body mass index between 19 and 35 kg/m2, inclusive. * serum ldl-c ≥ 2.6mmol/l (≤ 100 mg/dl) and ≤ 4.9 mmol/l (≤ 190 mg/dl) at screening. * fasting triglyceride \< 4.52 mmol/l (\< 400 mg/dl) at screening.
patient generated goals in mental health: better outcomes?

Conditions: Mental Health

Summary: researchers believe that clinical care can be improved by engaging patients and families directly in planning the care process. engagement efforts have included asking patients/families to provide information about whether they are getting better. but what does "getting better" mean? the merits of surveys, questionnaires, or rating scales have been widely discussed. should they be disorder-specific or global? what should the investigators do if patients have difficulty reading or understanding these instruments? investigators in the united kingdom have proposed a simple solution: ask the patients and families what their primary goal treatment goal is and track progress together on that goal (goal-based outcomes or gbo). although there has been some work to suggest that this is helpful, it has never been tested in a controlled way. this study will do a randomized controlled trial to test whether gbo improves clinical care in child and youth mental health. although the study will use this in child and youth mental health care, if it is successful, it can be tested and applied in any care setting with any type of medical problem. this could change practice at the children's hospital of eastern ontario (cheo) and throughout canada.


Eligibility criteria:
inclusion criteria: * children and youth * attending outpatient mental health services at cheo exclusion criteria: -child and youth attending group therapy at cheo outpatient mental health services

Keywords: depression psychosis personality disorder substance abuse
effectiveness of action observation therapy in stroke patients

Conditions: Stroke; Rehabilitation

Summary: the goal of this clinical trial is to learn the effectiveness of action observation therapy in patients with stroke. the main questions it aims to answer are: is action observation therapy an effective method in stroke patients? researchers will compare the results of two action observation-based exercises with conventional exercise to see whether action observation therapy works in the rehabilitation of stroke patients. participants: participants in one group will do action observation-based exercise for 24 sessions, while participants in the other group will do conventional exercise.

individuals with chronic stroke will be included in this study. participants will be randomly divided into two groups, and patients in both groups will continue their routine treatments. in addition to routine treatment, patients in the control group will be given an exercise program explained verbally and/or through pictures. patients in the study group will be given a home exercise program in addition to routine treatment. however, patients will be asked to first watch the video of each exercise in this program and then perform the exercise. patients will be asked to perform the exercises 3 days a week for 8 weeks. evaluations will be made twice, before the exercise program application begins and after the sessions are completed.

Eligibility criteria:
inclusion criteria: * stroke patients in the chronic phase (more than 6 months have passed since the stroke) * patients over 18 years of age * patients who can stand and walk independently (including those using walking aids) exclusion criteria: * additional disease (neurological, orthopedic, etc.) that may affect motor performance and balance. * patients with communication problems * patients aged 85 and over
efficacy and safety of irlanda-2 association on the treatment of common cold

Conditions: Common Cold

Summary: the purpose of this study is to evaluate the clinical efficacy of the drug associations in the treatment of common cold

double blind,randomized, multicenter; maximal experiment duration: 7 days; 03 visits; safety and efficacy evaluation

Eligibility criteria:
inclusion criteria: * participant within 48 hours of the onset of common cold symptoms: headache, sneezing, sore throat, nasal obstruction, cough, coryza and body pain; * signed consent. exclusion criteria: * patients with any clinically significant disease that, in the investigator opinion, can´t participate in the study; * patients with any laboratory finding or image finding that, in the investigator opinion, can´t participate in the clinical trial; * patients with history of hypersensitivity to any of the formula compounds; * participation in clinical trial in the year prior to this study; * patients with vaccine reaction; * patients who have uncontrolled asthma. however, participants in use of pulmonary corticosteroids (alone or in combination with other products) will be allowed if they are in stable dose and diagnosed with controlled asthma; * patients with gastroesophageal reflux, gastric or duodenal ulcer or other serious disease of the gastrointestinal tract; * patients with diabetes mellitus type i and ii; * pregnancy or risk of pregnancy and lactating patients; * patients in use of drugs that can interfere with flu symptoms evaluation.
comparison of two phacoemulsification-methods: low fluidic easytip 2.2mm vs. high fluidic easytip 2.2mm

Conditions: Cataracts

Summary: the aim of this study was to compare the intraoperative efficiency, safety and postoperative outcomes of cataract surgery with two different "high-fluidic" settings.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract * good overall physical constitution * locs 2-5 exclusion criteria: * previous intraocular surgery or ocular trauma * previous corneal pathology * previous endothelial cell count \<1200 * glaucoma * uveitis * pex * diabetic retinopathy and any other severe retinal pathology that would make a postoperative visual acuity of 20/40 (decimal equivalent = 0.5) or better unlikely * intraocular complication like posterior capsular * postoperative comlpications (e.g. postoperative uveitis)

Keywords: efficacy and safety
a randomized-controlled trial to examine the effects of a daily probiotic supplement on common symptoms of menopause

Conditions: Menopause

Summary: symptoms of menopause can significantly affect overall quality of life. it is hypothesized that probiotic supplements can reduce the severity of these symptoms. this 90-day randomized controlled trial will examine the effects of the provitalize natural menopause probiotic on weight loss, waist circumference, sleep, and symptoms of menopause including hot flashes, night sweats, mood swings, anxiety, fatigue and brain fog. participants will take either the test product or a placebo daily. all participants will complete study-specific questionnaires and provide sleep data from their fitbit at baseline, day 30, day 60 and day 90. at baseline, day 30, day 60 and and day 90, participants will also provide a bodyweight measurement and a waist circumference measurement.


Eligibility criteria:
inclusion criteria: * women aged 45-65 years old * must experience hot flashes and/or night sweats at least once per day * must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes * can be either natural or surgical menopause * has not had a period in the last 12 consecutive months * willing to adhere to the study protocol for the duration of the study * willing to stop taking any other herbal remedies or supplements for the duration of the study * self-reports as "generally healthy" * has never taken provitalize before * no planned invasive medical procedures for the duration of the study or in the three weeks leading up to the study start exclusion criteria: * not experiencing hot flashes and/or night sweats at least once per day and two other symptoms of menopause such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, irregular or absent periods, or vaginal changes * unwilling to stop taking any other herbal remedies or supplements for the duration of the study * current use of conventional hormone replacement therapies, or plan to start during the study duration * current use of hormonal birth control, or plan to start during the study duration * known allergies or hypersensitivities to any product ingredients * current or history of uterine fibroids, endometriosis, polycystic ovarian syndrome, or history of abnormal pap smear * anyone with any known severe allergies requiring the use of an epi-pen * unwilling to adhere to the study protocol * anyone living with uncontrolled or chronic health disorders, including oncological or psychiatric disorders * pregnant, breastfeeding or trying to conceive * currently taking a prescription sleep aid